China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with compatriot firm TaiGen Biotechnology Co., Ltd. Under the terms of the agreement, Joincare will take exclusive development, manufacturing, and commercialization rights to TaiGen’s PA endonuclease inhibitor TG-1000, as well as its derivatives, in the Greater China market, which includes Chinese mainland, Hong Kong, and Taiwan.
Financial and Development Responsibilities
Joincare will pay TaiGen RMB 20 million (USD 2.9 million) in upfront and milestone payments, along with an 11% sales commission fee. The company will be responsible for advancing the clinical study for the drug in China.
TG-1000: Advantages and Clinical Progress
TG-1000 is being developed to treat uncomplicated patients with acute infection of simple influenza A and B. It has concluded Phase II clinical trials in China, with Phase III trials confirmed and set to commence soon. Existing data indicate that TG-1000 offers several advantages, including rapid onset, long viral inhibition time, good tolerance, and oral administration not affected by food. Additionally, it is not prone to drug resistance and can effectively inhibit both influenza A and B viruses simultaneously.-Fineline Info & Tech
